Hong Kong · Delayed Price · Currency is HKD WuXi Biologics Earnings Call Transcripts
Fiscal Year 2026
-
PatroLab and TrueSite technologies are driving automation and cost reductions, while project momentum remains strong with a 50% YoY increase and expanded capacity. Revenue growth guidance is reaffirmed at 13%-17% (16%-20% ex-FX), with manufacturing and biosimilar segments set for rapid expansion.
-
A scaled CRDMO platform is driving rapid growth through complex biologics, global expansion, and technology leadership. Royalties and milestones are rising, with bispecifics and ADCs fueling high-margin revenue. New sites and automation support a strong outlook into 2026.
Fiscal Year 2025
-
Record 2025 results with double-digit revenue and profit growth, margin expansion, and strong global project wins. Guidance for 2026 is 13%-17% revenue growth, reflecting currency and macro uncertainties, with continued investment in technology and capacity.
-
Record-high revenue and profit growth in H1 2025, driven by strong project wins, manufacturing expansion, and high-margin IP-based income. Margins improved, guidance raised, and global expansion milestones achieved, with robust cash position and positive outlook for accelerated growth.
-
The session highlighted robust growth in early-stage projects, global expansion, and operational innovation, with strong financial performance and margin improvements expected. Technology leadership in disposable manufacturing and a resilient business model position the company for accelerated growth through 2026.
Fiscal Year 2024
-
Revenue grew 9.6% in 2024 (13.1% excluding COVID), with strong project additions and margin expansion. Outlook for 2025 is robust, targeting 12-15% revenue growth, driven by commercial manufacturing and global expansion.
-
Solid H1 2024 results with 7.7% non-COVID revenue growth and 61 new projects added. Adjusted net profit fell 13% due to timing of milestone deals, but full-year guidance is maintained with stronger profitability expected in H2.